|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||173.11 - 175.43|
|52 Week Range||169.61 - 256.80|
|PE Ratio (TTM)||5.29|
|Earnings Date||Feb 6, 2018 - Feb 12, 2018|
|Forward Dividend & Yield||2.80 (1.60%)|
|1y Target Est||230.89|
Teva is actively making progress toward divestiture opportunities. In November 2017, it divested Paragard to Cooper Surgical for $1.1 billion.
The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced manufacturing and R&D facilities. Though their businesses are recession-proof, a huge portion of their expenses has to be allocated to research and development to stay ahead of the competition. Medicine has […]
DUBLIN, Nov. 22, 2017 /PRNewswire/ -- Allergan plc (AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the 2017 Citi Global Healthcare Conference in New York City. The presentation will be webcast live and can be accessed on Allergan's Investor Relations website at www.allergan.com/investors. Allergan plc (AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
DUBLIN, Nov. 16, 2017 /PRNewswire/ -- Allergan plc (AGN), a leading global biopharmaceutical company, today announced that David Nicholson, Allergan's Chief Research and Development Officer, and Armin Szegedi, Allergan's Vice President of Clinical Development/CNS, will present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference in Boston, Massachusetts. The presentation will be webcast live and can be accessed on Allergan's Investor Relations website at www.allergan.com/investors. Allergan plc (AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
In 3Q17, Novartis's (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).
Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.
DUBLIN and CHARLESTON, S.C., Nov. 14, 2017 /PRNewswire/ -- Allergan, Inc. (AGN), in partnership with the National Association For Continence (NAFC), today announced the results of a new survey that revealed the impact of overactive bladder (OAB) and related symptoms on those living with the condition, as well as the extremes to which people will go to cope with or hide their symptoms. "People can start experiencing symptoms of OAB at an early age, learning to settle for a lifetime of silently struggling with an uncomfortable condition," says Steven Gregg, PhD, Executive Director of the NAFC. The survey found that 86 percent of respondents experience OAB symptoms multiple times a day.
Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker. Botox maker Allergan said in a filing with the Securities and Exchange Commission that it will sell 25 million shares to a JP Morgan Chase and Co unit - acting as a dealer for the shares - sometime next quarter. The JP Morgan unit will pay a price based on the average trading price over a yet-to-be determined period before the sale.
Amgen (AMGN) received positive CHMP opinion to expand Nplate's label to include pediatric patients and also for the marketing application of Avastin biosimilar.
Allergan plc said Monday it has won U.S. Food and Drug Administration approval for use of Vraylar in the maintenance treatment of schizophrenia. The FDA approved the company's supplemental new drug application ...
-- Label Expansion Includes New Data Showing Long-Term VRAYLAR Therapy Delayed Time to Relapse Compared to Placebo Over the Course of up to 72 Weeks -- DUBLIN , Nov. 13, 2017 /PRNewswire/ -- Allergan plc ...
THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (AMGN) and Allergan plc. (AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to Avastin® (bevacizumab).
DUBLIN , Nov. 8, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced its data will be presented at the annual American Academy of Ophthalmology (AAO) ...
Democratic Senators Sherrod Brown, Maggie Hassan, Amy Klobuchar, Al Franken and Patty Murray made the request for documents in a letter to Allergan Chief Executive Brent Saunders. Allergan contends the tribe’s status as a sovereign entity places the patents outside the jurisdiction of the U.S. Patent Trial and Appeal Board, or PTAB.
A group of five senators said the deal was a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis.
Fitch cut Teva's credit rating by two levels, down to junk grade. HSBC analysts say shares could drop another 50% to $6.